GlassScriptPhysician profile
Neil I Steinberg
NPI 1467465781
$10,851.20
in general payments reported to CMS, 2019-2025
27 companies · $3,408 in 2025
The $3,408 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $166 · 2021: $77.25 · 2022: $1,286 · 2023: $2,451 · 2024: $2,666 · 2025: $3,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,498 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,497.80 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,653.48 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,262.57 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,256.32 | 2022-2025 | Vraylar |
| Lundbeck LLC | $907.49 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $865.41 | 2019-2025 | Spravato, Invega Trinza, Invega |
| Vanda Pharmaceuticals INC. | $721.36 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $670.01 | 2023-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $507.22 | 2019-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $446.81 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $416.48 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $397.96 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $274.60 | 2021-2025 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $250.24 | 2022-2023 | Quviviq |
| Corium, LLC | $216.07 | 2023-2025 | Azstarys, Azstarys |
| E.R. Squibb & Sons, L.L.C. | $194.13 | 2024-2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $174.71 | 2023-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $169.14 | 2024-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $125.21 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $88.14 | 2025 | Jornay Pm |
| Allergan, INC. | $73.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $57.03 | 2019-2023 | Austedo |
| Noven Therapeutics, LLC | $33.21 | 2023 | Xelstrym |
| Shire North American Group INC | $32.89 | 2019 | |
| Neuronetics, INC. | $29.04 | 2019-2023 | Neurostar Tms Therapy System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.49 | 2024 | |
| Adlon Therapeutics L.P. | $11.07 | 2019 | |
| Validus Pharmaceuticals LLC | $0.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.